Sixty-seven percent of GA101-treated patients experience a serious side effect, including 34% reporting significant drops in white blood cell counts known as neutropenia. By comparison, the rate of serious adverse events associated with chemotherapy was 41 percent, including 15% occurrence of neutropenia.
These are the data Roche filed with FDA seeking GA101's approval but investors are more interested in how GA101 stacks up against Rituxan. The second stage of the phase III study is not ready for a final analysis, but preliminary data released Wednesday shows GA101 might be a better drug.
CLL patients treated with Rituxan reported a median PFS of 15.7 months, which is numerically inferior to the 23-month median PFS for GA101. The Rituxan data will change, however, as the study matures. Roche expects to have more definitive results from the second stage of the study later this year.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts